The results of clinical trials showed that CAD106 has a favorable safety and well tolerability, and the antibody response correlated negatively with Aβ accumulation (NCT00733863, NCT00411580, NCT00795418, NCT00956410, NCT01023685). A recent clinical trial (NCT02565511, phase II/III) combined BACE-1 inhibitor umibecestat and CAD106 was tested in 60- to 75-year-old participants with high genetic risk for AD. Most of participants in the treatment group observed plaque formation deceleration. However, the study was prematurely terminated. The gene discussed is BACE1; the disease is Alzheimer disease.